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Background: A common event in the development of human neoplasia is the
inactivation of a damage-inducible cell-cycle checkpoint pathway regulated by
p53. One approach to the restoration of this pathway is to mimic the activity of
key downstream effectors. The cyclin-dependent kinase (Cdk) inhibitor p21WAF1
is one such molecule, as it is a major mediator of the p53-dependent growth-
arrest pathway, and can, by itself, mediate growth suppression. The primary
function of the p21WAF1 protein appears to be the inhibition of G1 cyclin–Cdk
complexes. Thus, if we can identify the region(s) of p21WAF1 that contain its
inhibitor activity they may provide a template from which to develop novel anti-
proliferative drugs for use in tumours with a defective p53 pathway.
Results: We report on the discovery of small synthetic peptides based on the
sequence of p21WAF1 that bind to and inhibit cyclin D1–Cdk4. The peptides and
the full-length protein are inhibitory at similar concentrations. A 20 amino-acid
peptide based on the carboxy-terminal domain of p21WAF1 inhibits Cdk4 activity
with a concentration for half-maximal inhibition (I0.5) of 46 nM, and it is only four-
fold less active than the full-length protein. The length of the peptide has been
minimized and key hydrophobic residues forming the inhibitory domain have
been defined. When introduced into cells, both a 20 amino-acid and truncated
eight amino-acid peptide blocked phosphorylation of the retinoblastoma protein
(pRb) and induced a potent G1/S growth arrest. These data support a
physiological role for the carboxyl terminus of p21WAF1 in the inhibition of Cdk4
activity. 
Conclusions: We have discovered that a small peptide is sufficient to mimic
p21WAF1 function and inhibit the activity of a critical G1 cyclin–Cdk complex,
preventing pRb phosphorylation and producing a G1 cell-cycle arrest in tissue
culture cell systems. This makes cyclin D1–Cdk4 a realistic and exciting target
for the design of novel synthetic compounds that can act as anti-proliferative
agents in human cells.
Background
Tumour suppression by p53 is linked to a cell-cycle check-
point induced by DNA damage [1], in which p53 can
induce either growth arrest [2] or apoptosis [3–5] in the
damaged cells. The biochemical activity of p53 most tightly
associated with tumour suppression and growth arrest
involves a damage-dependent activation of sequence-spe-
cific transcriptional activity [1,6,7]. p53 induces the tran-
scription of a number of genes, the products of which
directly mediate growth arrest. These p53-inducible nega-
tive regulators of cell proliferation include: the cyclin
dependent kinase (Cdk) inhibitor (CKI), p21WAF1 [8–11];
an apoptosis-promoting protein, Bax [12]; the insulin
growth factor binding protein, IGF-BP3 [13]; and Gadd45
[14], a potent inhibitor of cell proliferation with an as yet
unclear biochemical function [15].
Inactivation of the damage-inducible cell-cycle check-
point pathway regulated by p53 is a common event in the
development of human neoplasia [16,17]. A variety of
mechanisms can lead to the functional inactivation of the
p53 pathway, including missense mutations or deletions of
the p53 gene, inactivation of wild-type p53 protein func-
tion by interaction with the oncogenic cellular protein
mdm-2 [18], or the inability to induce downstream effec-
tor molecules, such as p21WAF1 [19,20]. Our growing
knowledge of the molecular mechanisms underlying the
transformation of mammalian cells offers the opportunity
to create rationally designed inhibitors of specific bio-
chemical processes essential to cell proliferation or cancer.
Recent developments have shown that the reactivation of
the p53 pathway in some human tumours could in theory
be achieved by several means. The biochemical function
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of mutant p53 protein could be activated [21,22], possibly
using small peptides as leads for drug design [23]. The
interaction of the oncogene mdm-2 and wild-type p53
could be disrupted through the use of peptidomimetic
inhibitors of complex formation [24]. Finally, the function
of the downstream effector molecule p21WAF1, which on
its own is capable of mediating growth suppression [8,25],
could be restored or mimicked. 
The p21WAF1 protein appears to act during growth
suppression primarily as an inhibitor of the G1 cyclin–Cdk
complexes [26–29]. Here, we describe functional studies
of the interaction of small peptides derived from p21WAF1
with cyclin D1–Cdk4 complexes. This cyclin–Cdk
holoenzyme complex was chosen because the D-type
cyclins are required for cell-cycle progression in G1 phase
[30,31], and inhibition of the cyclin D-associated kinase
Cdk4 (along with its isoform Cdk6) leads to an arrest of
the cell cycle in G1 phase [32]. Thus, the cyclin D1–Cdk4
complex is a good target for the development of com-
pounds aimed at preventing cell proliferation.
With the aim of identifying low molecular weight peptide
mimetics of full-length p21WAF1 protein that could function
in cells, we carried out a systematic study to examine the
binding and inhibitory properties of a library of synthetic
peptides based on the amino-acid sequence of p21WAF1.
These studies have led to the identification of low molecu-
lar weight mimetics of the p21WAF1 protein that act as
growth inhibitors in vivo. These data have exciting implica-
tions for the mechanism of action of p21WAF1 protein and
represent a starting point for a drug design programme
aimed at producing small synthetic molecules that function
as tumour suppressors downstream of p53. 
Results
Peptides from the carboxyl terminus of the p21WAF1 protein
are potent inhibitors of Cdk4 activity
A major advance in research aimed at replacing downstream
effectors of p53 activity in human tumour cells would be to
produce low molecular weight mimetics of p21WAF1. Using
a series of synthetic peptides that span the entire sequence
of the p21WAF1 protein (Fig. 1a), we determined whether
any of these peptides could mimic full-length p21WAF1
protein in vitro by assaying for binding to cyclin D1 and
Cdk4, and for inhibition of Cdk4 catalytic activity. 
Using the previously described peptide precipitation assay
[32], we identified three domains of p21WAF1 that form
stable complexes with cyclin D1 and/or Cdk4 (Fig. 1b).
Domain 1 consists of peptide 2, which binds stably only to
cyclin D1 and contains the LeuPheGly motif essential for
the interaction of the p21WAF1 family with cyclins [33–35].
Domain 2 consists of peptide 4, which only binds stably to
Cdk4 and spans a region of p21WAF1 implicated in Cdk2
interactions [35–38]. Domain 3 comprises peptides 10 and
11, which have not been shown previously to be involved
in direct binding to cyclin D1 or Cdk4. 
The binding of domain 1 and domain 2 peptides (Fig. 1b)
are consistent with previously published physiological
72 Current Biology, Vol 7 No 1
Figure 1
The ability of peptides from p21WAF1 to interact with and inhibit cyclin
D1–Cdk4. (a) A list of the peptides (1–11) based on the sequence of
p21WAF1. (b) The p21WAF1 peptides were bound to streptavidin-agarose
beads and added to reticulocyte lysates containing either Cdk4 or cyclin
D1 labelled with [35S]methionine. After extensive washing, bound
proteins were analysed using SDS-PAGE followed by autoradiography.
The bands were quantified using a Bio-Imager and Whole Band Analysis
Software (Millipore). The results are representativeof three such
experiments. (c) Cyclin D1–Cdk4 kinase assays were carried out in vitro
using lysates from Sf9 insect cells following co-infection with Cdk4 and
cyclin D1 baculovirus constructs and using GST–Rb as the substrate.
p21WAF1 peptides were added to the assays at a concentration of
17 mM, and the effect on Cdk4 activity was assessed by SDS-PAGE
and autoradiography. The data are representative of four experiments.
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data showing that the amino-terminal half of the p21WAF1
protein is required for binding to the cyclin–kinase
complex [26,28,34]. This is, however, the first time that
small peptides from the amino terminus have been shown
to interact directly with either cyclin or Cdk, thus estab-
lishing that these regions of the p21WAF1 protein are not
only necessary but sufficient for stable binding to either
cyclin D1 (domain 1) or Cdk4 (domain 2). Strikingly,
domain 3 peptides define a region from the carboxyl ter-
minus of p21WAF1 that has not previously been shown to
play a physiological role in the regulation of cyclin
D1–Cdk4. This peptide domain differs from the other
two in that it appears to interact with both cyclin D1 and
Cdk4 (Fig. 1b). 
The p21WAF1 peptides that bind to the cyclin or Cdk
subunits may mimic the inhibitory activity of full-length
p21WAF1, providing a model for the design of p21WAF1
mimetics. The p21WAF1 peptides were therefore also
tested independently for inhibition of Cdk4 kinase to
determine if binding of peptides correlated with
inhibitory function. Using the retinoblastoma protein
(pRb)-phosphorylation assay, we identified two domains
of p21WAF1 with inhibitory activity (Fig. 1c). The inhibi-
tion of Cdk4 activity by peptide 2 (domain 1) correlates
with its ability to interact stably with cyclin D1 (Fig. 1b),
and suggests there may be an allosteric component to
Cdk4 regulation (our unpublished observations). These
data are also consistent with previous reports showing
that the amino-terminal half of p21WAF1 is required for
kinase inhibition [26,28,34,37]. In addition, the pro-
nounced inhibition by peptides 10 and 11 (domain 3)
defines a potent Cdk4 inhibitory region. This inhibition
also correlates with the ability of these peptides to bind
to cyclin and kinase subunits (Fig. 1b). Interestingly,
although we have identified a small peptide with a high
binding affinity for Cdk4 (domain 2), it has no inhibitory
activity when added to kinase assays at concentrations of
up to 35 mM. This suggests that compounds that mimic
p21WAF1 by binding to the Cdk4 subunit may not prove
to be good templates for the design of anti-proliferative
drugs.
A titration of peptides from domain 1 (peptide 2),
domain 2 (peptide 4), and domain 3 (peptide 10) was
performed to determine their relative potency as kinase
inhibitors (Fig. 2). The carboxy-terminal domain
(peptide 10) had the highest activity, with a concentra-
tion for half-maximal cyclin D1–Cdk4 inhibition (I0.5) of
0.1 mM. Based on these biochemical studies, peptide 10
defines a potent lead for the design of small synthetic
peptides that bind to and inhibit cyclin D1–Cdk4 kinase.
The remainder of this report describes the characteriza-
tion of this peptide in vitro and studies to determine
whether the peptide has biological activity as an inhibitor
of cellular proliferation.
Carboxy-terminal peptide 10 inhibits cyclin D1–Cdk4
specifically
p21WAF1 displays selectivity for the G1- and S-phase
cyclin–Cdk complexes [27]. We examined the specificity
of peptide 10 by determining its I0.5 for the inhibition of
cyclin E–Cdk2 and cyclin B–Cdc2. When added to kinase
assays at concentrations up to 20 mM, peptide 10 had no
significant effect on cyclin B–Cdc2 histone H1 kinase
activity (Fig. 3). It did, however, inhibit the activity of
cyclin E–Cdk2. The I0.5 for the inhibition was 4 mM,
which is ~40-fold higher than the I0.5 for cyclin D1–Cdk4.
Thus, the p21WAF1-based inhibitor, peptide 10, has a
much higher specific activity against cyclin D1–Cdk4 than
cyclin E–Cdk2 and, in common with full-length p21WAF1
protein, is a very poor inhibitor of cyclin B–Cdc2.
Identification of the inhibitory motif and minimization of
the lead peptide
To produce a realistic template for the design of novel
anti-proliferative drugs, we wished to determine if the
length of our inhibitory peptide could be significantly
reduced whilst retaining some inhibitory activity. Residues
Research Paper  Peptide inhibitors of Cdk4 from p21WAF1 Ball et al. 73
Figure 2
Quantification of inhibition by peptides. Peptides 2 (l), 4 (o), 8 (n)
and 10 (m) were added to cyclin D1–Cdk4 assays at various
concentrations between 0.01 and 34 mM, and GST–Rb
phosphorylation was measured. At the top is a plot of the percentage
activity (relative to Cdk4 activity measured in the absence of peptide)
against peptide concentration. At the bottom, the I0.5 for each peptide
is tabulated. The data represent the mean of three experiments.
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that were required for peptide function were first identi-
fied using a series of peptides, based on peptide 10, in
which each residue was sequentially mutated to alanine
(alanine scan; Fig. 4). We identified three residues,
within a stretch of just five amino acids, as being
extremely important for activity. The five amino acids
formed an inhibitory motif, RRLIF (amino acids 155–160,
in the single-letter amino-acid code), where the residues
in bold are essential for activity and the underlined
residue contributes towards inhibitory activity. The fact
that a single point mutation in either of two hydrophobic
residues (the leucine or phenylalanine residues) com-
pletely abolishes inhibitory activity suggested that inhibi-
tion was the result of a specific interaction at key
hydrophobic residues. In addition, these data establish
that the carboxy-terminal Cdk4-inhibitory motif and the
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Figure 3
The inhibition by peptide 10 is specific to
certain cyclin–Cdk complexes. The ability of
peptide 10 to inhibit the activity of other
cyclin–Cdk enzymes was assessed using
cyclin E–Cdk2 and cyclin B–Cdc2. The
kinase activity assays were performed using
Sf9 cell lysates, which were co-expressing
either human cyclin E and Cdk2, or human
cyclin B and Cdc2. The conditions were
identical to those described for cyclin
D1–Cdk4 assays, except that histone H1
(0.5 mg per assay) was used as a substrate
where indicated. The assays were carried out
in the presence of increasing concentrations
of peptide 10 (0.1, 0.5, 5, 20 mM).
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Figure 4
Alanine-scan mutations and minimization of
the length of peptide 10. (a) To pinpoint
residues that are critical for the inhibition of
Cdk4 by peptide 10, a series of point
mutations were constructed in which each
residue was sequentially changed to alanine.
The peptides were added to cyclin D1–Cdk4
assays and the results were analysed by SDS-
PAGE and autoradiography before (b)
quantification using a Bio-Imager. The results
are expressed relative to Cdk4 activity in the
absence of peptide and are representative of
three experiments. (c) Having identified the
critical residues we then synthesized an
untagged eight amino-acid peptide
(KRRLIFSK) that contains the critical arginine,
leucine and phenylalanine residues. The
phosphorylation of GST–Rb by cyclin
D1–Cdk4 in the presence of various
concentrations of this truncated peptide are
shown.
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PCNA-binding motif of p21WAF1 [39,40] are distinct from
one another.
Having identified residues that appeared to be critical for
the inhibition of cyclin D1–Cdk4 by peptide 10, we deter-
mined if these residues were in fact sufficient for inhibi-
tion, or if they had to be presented within the context of a
larger peptide. Strikingly, the eight amino-acid peptide,
KRRLIFSK, retained the ability completely to inhibit
cyclin D1–Cdk4 activity and prevent phosphorylation of
pRb (Fig. 4). The I0.5 for the truncated peptide was,
however, ~1000-fold higher than that of the full-length
peptide (I0.5 for the truncated peptide was ~100 mM).
This was not an unexpected result, as other studies have
shown loss of potency upon reducing the length of bioac-
tive peptides. It may, however, be possible to improve the
peptide inhibitory activity by manipulating the non-essen-
tial residues in a manner defined by Li et al. [41] in an
elegant series of experiments aimed at minimizing the
length of the atrial natriuretic peptide.
A substituted peptide 10 approaches the specific activity of
full-length p21WAF1
Whilst carrying out the alanine scan experiments, we
noticed that one of the mutant peptides (AspÝAla at posi-
tion 9 of peptide 10; Fig. 4) was a better inhibitor of Cdk4
activity than the wild-type peptide. We determined the I0.5
for this peptide and compared it with that of peptide 10,
full-length purified p21WAF1, and a peptide derived from
the tumour suppressor protein p16INK4 that has been
reported to inhibit Cdk4 activity in vitro and to prevent
cell-cycle progression [32]. The AspÝAla mutation
decreases the I0.5 of the full-length peptide 10 from 100 nM
to 46 nM (Fig. 5). Comparing this with the p16INK4-based
peptide, which has an I0.5 of 16.3 mM (Fig. 5), reveals that
we have produced a peptide that is ~350-fold more active
than the p16INK4-based peptide as a Cdk4 inhibitor. In fact,
this peptide functions within the physiological range of
p21WAF1 itself, which has an I0.5 of 11 nM (Fig. 5). We do
not know why the substitution of alanine for this aspartic
acid, which is well outside the domain shown to be essen-
tial for activity, reduces the I0.5. It seems likely that the
altered residue changes the presentation of the inhibitory
motif rather than functioning directly in inhibition, as this
mutation does not appear to increase the affinity of the
peptide for either Cdk4 or cyclin D1 (data not shown).
Thus, we have now designed a peptide that has only a four-
fold lower specific activity than full-length p21WAF1.
Inhibition of proliferation and pRb phosphorylation in
human cells
We and others have recently shown that a 16 amino-acid
sequence from the homeodomain of the Antennapedia
protein can act as a carrier for peptides with biological activ-
ity, translocating them across the plasma membrane and
allowing them to interact with their target molecules
[32,42]. To determine if peptide 10 retains its biological
activity when introduced into tissue culture cells, a
chimaeric peptide, containing both carrier and peptide 10
sequences, was synthesized and added to a culture of prolif-
erating asynchronous human-keratinocyte-derived HaCaT
cells, which are mutant for p53 [43]. The linked peptide
(peptide I; Fig. 6) contained a MetÝAla mutation at posi-
tion 7; this abolished any PCNA binding function [39,40],
and allowed us to study the PCNA-independent effects of
the peptide in cells. 
Peptide I was added to the culture media at a concentration
of 25 mM. The cells were fixed 24 hours later and analysed
by fluorescence-activated cell sorting. Figure 6b,c shows
the cell-cycle distribution of untreated and peptide I-
treated cells assayed using bromodeoxyuracil (BrdU). The
number of cells entering S phase in the presence of peptide
I was dramatically reduced as compared with the control,
and the number of cells in G1 showed a concomitant
increase. This suggests that peptide I mimics the ability of
full-length p21WAF1 to act as a growth suppressor by
inducing a G1 cell-cycle arrest. Similar studies with human
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Figure 5
Comparison of inhibitory peptides with full-length p21WAF1 protein. Top:
concentration curves for peptide 10 (m), AspÝAla mutant peptide 10
(l), a p16INK4-derived peptide (n) [32] and full-length p21WAF1 (t) were
determined using the cyclin D1–Cdk4 assay analysed by SDS-PAGE,
autoradiography and bio-imaging. Bottom: the I0.5 of each inhibitor. The
results are the mean of three such experiments.
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breast cancer (MCF7) and fibroblast (MRC5) cells show
that the p21WAF1 peptide can also function in cells with
wild-type p53 (Fig. 6g). 
To ascertain if peptide I was functioning as a growth
inhibitor by preventing the phosphorylation of pRb in 
a manner analogous to p21WAF1, HaCaT cells were
synchronized by serum starvation. Peptide I was added to
the cells at the same time as they were released from
serum starvation, and samples from treated and untreated
cells were taken over a 24-hour period. The phosphoryla-
tion status of pRb was monitored by a gel mobility shift
assay (Fig. 6h). pRb became hyperphosphylated between
12 and 15 hours after serum was added to starved cells, but
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Figure 6
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Induction of growth arrest by peptide 10. (a) A series of synthetic
peptides based on the sequence of peptide 10 (peptides I, II and III)
were synthesized with carrier peptide (shaded sequences). Peptide I has
the peptide 10 sequence, peptide II the minimal eight amino acids, and
peptide III the peptide 10 sequence less a few hydrophobic amino acids
essential for inhibitory activity. The underlined residue in peptide I is the
MetÝAla mutation that prevents PCNA binding. The peptides were
added to proliferating cells grown in DMEM plus 10 % FCS. The cells
were incubated for 24 h, pulse labelled during the last 30 min with
15 mM BrdU, fixed and then analysed by FACS. (b–e) The cell-cycle
distribution for HaCaT cells that were either (b) untreated or treated with
(c) peptide I at 25 mM, (d) peptide II at 50 mM or (e) peptide III at 25 mM.
(f) The data from (b–e) area shown as the percentage of HaCaT cells in
each phase, compared to the total number of cells counted. (g) The
results of similar experiments, carried out using MCF7 and MRC5 cells.
The table shows the percentage of cells in each phase of the cell cycle
in these cells in the absence and presence of peptide I. (h) FCS alone or
FCS containing either 25 mM peptide I or 50 mM peptide II was added
to HaCaT cells that had been starved for 72 h. Samples were taken at
the times shown and analysed by SDS-PAGE followed by a western blot
stained for pRb. The band labelled pRb represents hypophosphorylated
Rb protein, and pRb* refers to hyperphosphorylated Rb protein. Equal
amounts of total protein were loaded per lane, but the antibody appears
to preferentially recognize phosphorylated forms of the Rb protein.
in the presence of peptide I pRb remained hypophospho-
rylated. In addition, when peptide 10 was added to syn-
chronous HaCaT cells 14 hours after serum stimulation (as
the cells were passing through the restriction point at
which pRb becomes hyperphosphorylated) its effect on
cell-cycle distribution was greatly diminished (data not
shown). Together, these data indicate that peptide I
causes a G1 arrest in human HaCaT cells by preventing
the phosphorylation of pRb.
In similar experiments with proliferating HaCaT cells, we
introduced the eight-amino-acid bioactive derivative of
peptide 10 (Fig. 6d; peptide II), and a control peptide 10
that lacked the hydrophobic residues which are essential
for Cdk4 inhibition (Fig. 6e; peptide III). We found that
peptide II effectively promoted a G1-phase arrest and pre-
vented the phosphorylation of pRb when added at 50 mM
(Fig. 10h). Peptide III, however, had no significant effect
on the ability of HaCaT cells to enter S phase. It is inter-
esting that the truncated peptide 10, when coupled to
carrier peptide (peptide II) and introduced into cells, is
only 2–4-fold less active as a growth suppressor than
peptide I. Linking the truncated peptide 10 to the carrier
peptide may promote a more favourable inhibitory confor-
mation, as the I0.5 for the carrier-linked truncated peptide
(peptide II) in vitro is ~50-fold less than that of the free
truncated peptide (data not shown).
Discussion
Identification of a physiologically relevant Cdk4 regulatory
site from the carboxyl terminus of p21WAF1
Synthetic peptides or peptidomimetics are proving to be
useful in studying the biochemical regulation of enzymes
and proteins, and also in providing models for the design
of novel anti-proliferative agents targeted to the proteins
or enzymatic pathways that are altered or activated in
human tumours [44,45]. Several peptides have been
shown effectively to target components of the cell-cycle
machinery. These include farnesyl-transferase inhibitor
(FTI), which inhibits farnesyl protein transferase prevent-
ing the activation of Ras [46], Ras effector domain pep-
tides, which can inhibit the biological function of Ras
[47,48], polypeptides containing SH2/SH3 domains,
which in theory should inhibit the growth of tumours with
activated tyrosine kinases [49,50], and p16INK4-derived
peptides, which inhibit cyclin D–Cdk complex activity
and thereby activate pRb-dependent cell-cycle arrest [32].
Inactivation of the tumour suppressor protein p53 is a
common event in the development of human neoplasia
[16]. The p53 protein is a key player in an inducible cell-
cycle checkpoint pathway activated in response to DNA
damage and perturbation of nucleotide pools [2,17]. Reac-
tivation of this pathway by the restoration of p53 function
could therefore provide a route to a novel anti-prolif-
erative therapy. In general, however, the pharmacological
restoration of biochemical function to a protein that has
lost its normal activity through mutation of its amino-acid
sequence is more difficult than the inhibition of a bio-
chemical function [45]. Thus, it may prove more produc-
tive to take alternative approaches to restore activity to the
p53 pathway, such as mimicking the inhibitory activity of
the downstream effector molecule p21WAF1, which can by
itself mediate growth arrest primarily through its
interaction with the G1 cyclin–Cdk complexes [8,25,27].
We have identified a region from the carboxyl terminus of
p21WAF1 that is important for interactions with G1
cyclin–Cdk complexes, and we are using this region as a
template to design novel anti-proliferative agents. A
peptide based on this region bound to and potently inhib-
ited cyclin D1–Cdk4 in vitro, and retained biological activ-
ity when introduced into proliferating cells. A peptide
composed of amino acids 141–160 of p21WAF1 inhibited
Cdk4 activity with an I0.5 of 0.1 mM, and caused cycling
cells to arrest at the G1/S-phase boundary. In addition, we
have shown that there is scope for producing peptides with
improved activity, as mutations introduced into peptide 10
have reduced its I0.5 to 46 nM. This compares favourably
with the I0.5 of full-length p21WAF1 protein (11 nM). 
Peptide 10 represents a potentially exciting lead for
rational drug design, as it is by far the most potent peptide
inhibitor of Cdk activity discovered to date, with the
AspÝAla mutant peptide being ~350-fold more potent
than the recently identified p16INK4 peptide [32]. The fact
that the peptide retains biological activity when reduced
to just eight amino acids improves its appeal as a template
for drug design. In general, protein–protein interfaces are
relatively large, relying on the participation of 10–30
contact sidechains on each interface, with each region of
contact often being composed of residues that are dis-
persed throughout the primary amino-acid sequence
[51,52]. There is evidence, however, that in some cases
only a small subset of these sidechains need to be con-
tacted for efficient binding to occur [53,54]. Our discovery
that a single eight amino-acid peptide is sufficient to
inhibit the activity of a critical G1 cyclin–Cdk complex,
preventing pRb phosphorylation and producing a G1 cell-
cycle arrest in tissue-culture cells, suggests that interaction
at only a small subset of contact sidechains is necessary for
potent inhibition of cyclin D1–Cdk4 activity at the G1–S
phase boundary. This makes cyclin D1–Cdk4 a realistic
and exciting target for the design of small synthetic com-
pounds that can at act as anti-proliferative agents.
Specificity of p21WAF1 peptide leads for cyclin D1–Cdk4
Prior to our studies, no data on the direct interaction of
small peptides with either cyclins or Cdks had been
reported. In addition, no evidence existed to suggest that
a small peptide derived from the p21WAF1 protein would in
fact be biologically active as a Cdk inhibitor in cells. While
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this manuscript was under review, Chen et al. [33]
reported that a peptide based on the carboxyl terminus of
the p21WAF1 protein could prevent the formation of a
stable complex between p21WAF1 and cyclin E or A, and
that this peptide was a weak inhibitor of Cdk2 activity in
vitro. Although data were not presented showing that pep-
tides could bind directly to cyclins or Cdks, it was pro-
posed that the RRLI motif contained within peptide 10
represented a cyclin-interacting site comparable to that
contained within peptide 2, RRLF. However, in our direct
binding measurements we found that the mechanism of
action of peptide 10 was different to that of peptide 2, as
peptide 10 could bind to both cyclin D1 and Cdk4,
whereas peptide 2 could only bind to cyclin D1 (similar
results have also been obtained with cyclin D1 and Cdk4
expressed in Escherichia coli; data not shown). Although we
agree that peptides from the carboxy-terminal region of
p21WAF1 do not have a high specific activity for Cdk2 inhi-
bition, they are potent inhibitors of Cdk4 activity. 
The fact that Chen et al. [33] did not find peptides that
competed with p21WAF1 for binding to cyclin D1 may be
explained by their use of 12 amino-acid peptides. In the
present study, we found that the length of peptide 10 was
critical for stable binding. When non-critical residues
were removed from the amino terminus of the peptide, its
affinity for cyclin D1 and Cdk4 was greatly reduced. In
fact, the increase in I0.5 for the eight amino-acid truncated
version of peptide 10 reflects its inability to form a stable
complex with cyclin D1–Cdk4 (data not shown), suggest-
ing that the inhibitory motif may be given a favourable
inhibitory conformation by residues outside of the
RRLIF motif.
We have defined the residues that are important for
biochemical activity of the carboxy-terminal peptide from
p21WAF1 and find that the leucine and phenylalanine, but
not the isoleucine, are essential for both binding (data not
shown) and inhibition (Fig. 4), indicating that the
inhibitory binding motif is RRLIF. Our study points to
the importance of carrying out detailed mechanistic
studies on each cyclin–Cdk–CKI combination in order to
define accurately the specificity of the CKI for each
cyclin–Cdk complex. For example, removal of the amino-
terminal 34 amino acids (containing the cyclin-binding
motif found in peptide 2) from the Xenopus p21WAF1
homologue Xic1 results in a protein that is compromized
in its ability to inhibit cyclin A–Cdk2, but is still an effi-
cient inhibitor of cyclin E–Cdk2 activity [55]. In addition,
the crystal structure of the amino-terminal half of p27KIP1
suggests that the association of one molecule of p27KIP1
with cyclin A–Cdk2 is inhibitory [35]. This is in contrast to
the clear biochemical evidence that two molecules of the
p21WAF1 protein are required for Cdk inhibition, with
cyclin–Cdk complexes containing a single molecule of
p21WAF1 being catalytically active [27,56].
Conclusion
These studies have led to the identification of small
molecular weight mimetics of the p21WAF1 protein that act
in vivo as growth inhibitors by preventing the phosphory-
lation of pRb. We have identified novel binding peptides
that potently inhibit Cdk4 activity within the same physi-
ological concentration range as full-length p21WAF1. These
data pinpoint a cyclin D1–Cdk4 inhibitory motif and rep-
resent a starting point for a drug-design programme aimed
at producing small synthetic molecules functioning as
tumour suppressors downstream of p53. 
Materials and methods
Peptides
All biotinylated peptides were synthesized by Chiron Mimotopes, Peptide
Systems (Clayton, Australia). Each peptide had a biotin-SGSG spacer at
the carboxyl terminus and a free amino terminus. The peptides were dis-
solved in DMSO at ~5 mg ml–1. We then determined their concentration
precisely by amino-acid analysis. The purity of the peptides was esti-
mated using mass spectrometry. The truncated peptide 10 and peptides
for application to cells were kindly provided by Weng Chan; they were
synthesized using standard Fmoc/tBu solid-phase chemistry and deriva-
tized NovaSyn TG resin (Calbiochem-Novabiochem UK) on an auto-
mated peptide synthesizer (PepSynthesizer 9050; MilliGen/Biosearch
UK). The peptides were purified by reverse-phase HPLC on a semi-
preprative Hypersil Pep C18 column (Shandon HPLC, UK) using 0.06 %
aqueous TFA/acetonitrile gradient elution. The purity (> 95 %) was
established by HPLC and mass spectrometry (MS; either laser desorp-
tion-MS on a Kompact Maldi III; Kratos Analytical, or electrospray-MS on
a VG Platform; Fison).
Proteins
Cyclins and Cdks for kinase assays were co-expressed in Sf9 insect
cells infected with the appropriate baculovirus constructs. The cells were
harvested two days after infection by low-speed centrifugation and the
pellet was lysed in an equal volume of 10 mM Hepes, pH 7.4 containing
10 mM NaCl, 1 mM EDTA, 2 mM DTT and 0.1 mM phenylmethane
sulphonyl fluoride, before centrifugation at 14 000 xg for 15 min.
Labelled Cdk4 and cyclin D1 were produced by translation in the pres-
ence of [35S]methionine using a rabbit reticulocyte lysate in vitro transla-
tion kit (Promega).
Human His-tagged p21WAF1 was expressed in E. coli using a PET expres-
sion vector. The soluble p21WAF1 protein fraction was purified using a
nickel chelating column and gel filtration chromatography on a Superose
12 column, following the manufacturers instructions (Pharmacia). 
GST–Rb was produced using an E. coli expression construct containing
the hyperphosphorylation domain of pRb (amino acids 773–924). The
protein was purified on a glutathione-Sepharose column according to the
manufacturer’s instructions (Pharmacia).
Peptide precipitation of Cdk4 and cyclin D1
Peptide precipitation assays were performed as described [32]. The
bound protein was analysed by SDS-PAGE followed by auto-radiogra-
phy and quantification of the 35S-labelled protein using a Bio-Imager and
Whole Band Analysis Software (Millipore).
Enzyme assays
Cdk phosphorylation of GST–Rb was measured using the insect-cell
lysates described above. Extract (1 ml) was added to a final reaction
volume of 10 ml, containing 50 mM Hepes, pH 7.4, 10 mM MgCl2,
2.5 mM EGTA, 1 mM DTT, 10 mM b-glycerophosphate, 1 mM NaF,
10 mM PKI (protein kinase inhibitor) 50mM ATP containing [32P]ATP
(1000 cpm pmol–1). The assays were started by the addition of 0.5mg of
the substrate (GST–Rb or histone H1), incubated at 30 °C for 10 min,
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and terminated by adding SDS-PAGE sample buffer and heating at
95 °C for 4 min. The samples were analysed on 12 % SDS-PAGE gels
followed by autoradiography and quantification using a Bio-Imager. 
Cell-cycle measurements
Carrier-linked peptides were designed (Fig. 6a) for delivery into proliferat-
ing HaCaT cells. Cells were seeded on 30-mm-diameter culture plates
and grown to 50 % confluency in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10 % (v/v) foetal calf serum (FCS). Peptides
were added to the medium and the cells were incubated for 24 h. During
the last 30 min of the incubation, the cells were pulse-labelled in the
presence of 15 mM BrdU. The cells were trypsinized, fixed in absolute
alcohol and prepared for analysis by FACS using a single-laser flow
cytometer (Becton-Dickinson) [57]. 
pRb phosphorylation in HaCaT cells
HaCaT cells were seeded on 30-mm-diameter culture plates at 25 %
confluency in DMEM with 10 % FCS. The FCS was withdrawn after 24 h
and the cells were starved for 72 h. At the end of this period the medium
was supplemented with 10 % FCS and carrier-linked peptides. Samples
were taken over a 24 h time course by lysing the cells in RIPA buffer. The
phosphorylation status of pRb was determined by western-blot analysis
[32]; the blot was probed with the anti-pRb polyclonal antibody C-15
(Santa Cruz).
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